Ajinomoto Bio-Pharma Services              

Senior Partner


Ajinomoto Bio-Pharma Services is an established premier US-based provider for high containment ADC bioconjugation, offering process development, analytical development, formulation, clinical and commercial manufacturing and fill finish services, along with all supporting release and stability testing.

Developing ADCs? We offer significant advantages for next generation ADCs with AJICAP™, an innovative direct chemical site-selective conjugation method for intact native antibodies. Our advanced method allows for high productivity, short conjugation reaction times and ease of manufacture.



Senior Partner

MilliporeSigma is the leading Life Science company, providing solutions as a strategic partner to help advance the promise of life saving therapies. We have the largest offering of products for formulations, actives and biotechnology processes. Our joint ADC offering includes a full range of integrated contract manufacturing services for drug development and manufacturing that spans conjugation, mAbs, linkers and payloads. To fit your ADC manufacturing needs, we offer a comprehensive processing portfolio from cell culture media to buffers, salts and stabilizers and from chromatography to TFF equipment, including single-use templates.




Abzena is a leading contract provider of integrated discovery, development and manufacturing services for biologics and antibody drug conjugates (ADCs) for the global biopharmaceutical industry. Abzena provides complete solutions for integrated early discovery to mid-phase biotherapeutic and bioconjugation drug development and manufacturing.

With world-class experts capable of designing, producing and evaluating ADCs at every stage of the drug development process Abzena can produce fully characterised ADCs at low-mg to multi-kg scale with all known cytotoxins, release mechanisms and polymers using a broad range of conjugation technologies.

Abzena is owned by Welsh, Carson, Anderson & Stowe, one of the world’s leading private equity investors.

For more information, please see




Antikor are addressing challenges of treating solid tumours with their innovative next-generation ‘miniaturized’ Antibody Drug Conjugates (ADC) called Fragment Drug Conjugates (FDCs). FDCs offer benefits due to their effective penetration, more-rapid delivery of high amounts of cytotoxic payload and fast clearance from normal tissues, resulting in better tolerability and therapeutic index. Antikor has part-licenced its first product, an anti-HER2 FDC to development partner, Essex Biotechnology and Antikor’s exciting follow-up product will be disclosed at World ADC Summit 2020 in October. Antikor are looking for new development partners.




BioVectra is a Contract Development and Manufacturing Organization that serves global pharmaceutical and biotech companies with full-service cGMP outsourcing solutions for intermediates and active pharmaceutical ingredients. An innovative and reliable service partner with a strong regulatory history, we have over 50 years of experience specializing in:

  • cGMP microbial fermentation
  • Complex chemistry – high potency APIs
  • Biologics
  • Formulation development

We operate out of 4 cGMP facilities located in Atlantic Canada. For more information, please visit

Beacon 2017

Beacon Targeted Therapies


We are a competitive and research intelligence database solution designed in partnership with pharmaceutical professionals across the world. We work in targeted therapies to provide accurate, in-depth and real-time information in the rapidly evolving landscape of drug development.

Find out more on how we can help you by visiting

BSP Pharmaceuticals


BSP Pharmaceuticals is a Contract Development and Manufacturing Organization fully dedicated to antineoplastic  drugs, designed to handle the complexity of biopharmaceutical products and offering customized services to support its client from development to commercial manufacturing of injectables and oral formulations. BSP Pharmaceuticals is focused on innovative therapies such as Proteosome Inhibitors, Antibody Drug Conjugates (ADCs) , Liposomal formulations, handling the major platforms of ADC compounds currently in clinical and commercial phase.


CytomX Logo PMS



CytomX is a clinical-stage, oncology-focused biopharmaceutical company developing its novel Probody® platform to enable drugging previously considered undruggable targets. Our pipeline includes potential first-in-class therapeutic candidates CX-2009, a wholly owned CD166-targeting Probody drug conjugate, and CX-2029, a CD71-targeting Probody drug conjugate partnered with AbbVie, both of which are in Phase 2. Our clinical-stage portfolio includes potential best-in-class immunotherapeutic candidates against clinically validated targets. Our strategic collaborations include AbbVie, Amgen, Astellas and Bristol Myers Squibb.




We are a reliable supplier of HPAPIs for the pharmaceutical industry specialized in fighting cancer.

Besides our platinum-based and organic HPAPIs, we have an extensive knowledge in manufacturing and purification of different payload and linker classes in the ADC field.

As CDMO we support our customers in the exclusive synthesis of cytotoxic compounds from research stage to registration and market launch.

Heraeus, headquartered in Hanau, Germany, is a leading international family-owned company formed in 1851.

3. intocell Logo_(PNG) (1)



IntoCell is a Korea-based biotechnology company dedicated to the development and commercialisation of novel antibody drug conjugate platform technologies. The company has developed a state of the art linker technology comprising of a novel self-immolative group based on OHPAS (Ortho-Hydroxy Protected Aryl Sulfate) chemistry that works with a wide variety of phenolic and non-phenolic payloads. The OHPAS linker is designed to release phenolic payloads through intramolecular cyclization, mediated by ortho-hydroxyl group temporarily blocked by a triggering group. The technology has been extended to non-phenolics by introducing a phenolic spacer. The linker, with or without phenolic spacer, has been applied to full ADCs, which showed excellent dose dependent efficacy both in vitro and in vivo.


LegoChem Biosciences


LegoChem Biosiences is a clinical stage biotech with expertise in medicinal chemistry. It has several antibiotic programs for infectious disease with urgent needs and drugs in oncology and anti-fibrosis. It has extended its expertise to ADC and developed next-generation site-specific ADC platform with novel linker that improves stability of ADCs in blood circulation, effectively prevents premature drug release, efficiently facilitates liberation of the drug at targeted tumor cells and ultimately shows significant improved therapeutic index.




As a leader for contract development and manufacturing, Lonza Pharma & Biotech is recognized for our reliable, high-quality services, global capacity, innovative technology platform and extensive experience. We serve pharmaceutical and biotechnology companies globally striving to help reduce risk and increase chances of business success. Our broad capabilities span across biologics, small molecules, bioconjugates and cell and gene therapies. We manage projects from pre-clinical stage through to commercialization and our expertise covers both drug substance and drug product.

We believe that the best outcome – for you and for your patients – can only come as a result of a successful collaboration. Together, we can solve the next challenge and bring your next medicine to life.

Piramal Pharma Solutions logo_RGB

Piramal Pharma Solutions


Piramal Pharma Solutions is a contract development and manufacturing organization (CDMO), offering end-to-end development and manufacturing solutions across the drug life cycle. We serve our clients through a globally integrated network of facilities in North America, Europe and Asia. This enables us to offer a comprehensive range of services including Drug Discovery Solutions, Process & Pharmaceutical Development services, Clinical Trial Supplies, Commercial supply of APIs and Finished dosage forms. We also offer specialized services like development and manufacture of Highly Potent APIs and Antibody Drug Conjugation. Our capability as an integrated service provider & experience with various technologies enables us to serve Innovator and Generic companies worldwide. For more information and updates, please visit: | Social Media: Twitter, LinkedIn




Formed in 2015, PROVEO is now a Division of Cerbios focused on complete supply chain solution for Antibody Drug Conjugates (ADCs).

Thanks to the partnership with AGC Biologics and Oncotec, PROVEO offer best-in-class solutions for the integrated development and cGMP manufacturing of recombinant proteins (incl mAbs), cytotoxic drug-linker payload, conjugation, aseptic fill and lyophilization. Strengths of the three PROVEO partners secure a seamless and low risk ADC supply chain for clinical and commercial projects.


Quanta BioDesign


Quanta BioDesign manufactures monodisperse, single molecular weight dPEG® reagents for the conjugation and modification of antibodies, proteins, peptides, and other biomolecules, as well as for surfaces and particles. SuperHydrophilic™ dPEG® reagents provide extreme water solubility, biocompatibility, and low nonspecific binding in research and commercial applications. Using patented and proprietary processes, we design, synthesize, and manufacture to large scale all of our dPEG® products in Plain City, OH, USA for use in life science, diagnostic and therapeutic applications.




MabDesign is a French non-profit membership organization that aims to federate, mobilize and support the development of the industrial sector in the field of immunotherapy.

MabDesign provides strategic leverage and development opportunities for its members, through the creation of a unique directory of stakeholders; by developing specialized training solutions, by providing business development and marketing support; as well as the organisation and support of scientific events, thus promoting networking and innovation.

MabDesign already counts with 160+ members companies, both pharmaceutical and biotechnology industries, service providers, training organizations and equipment suppliers at the front line of technology innovation.